Literature DB >> 26993207

Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.

Ryusuke Murakami1, Noriomi Matsumura2, Masaki Mandai3, Kosuke Yoshihara4, Hiroshi Tanabe5, Hidekatsu Nakai6, Koji Yamanoi1, Kaoru Abiko1, Yumiko Yoshioka1, Junzo Hamanishi1, Ken Yamaguchi1, Tsukasa Baba1, Masafumi Koshiyama1, Takayuki Enomoto4, Aikou Okamoto5, Susan K Murphy7, Seiichi Mori8, Yoshiki Mikami9, Sachiko Minamiguchi10, Ikuo Konishi1.   

Abstract

Recently, The Cancer Genome Atlas data revealed four molecular subtypes of high-grade serous ovarian carcinoma (HGSOC) exhibiting distinct prognoses. We developed four novel HGSOC histopathological subtypes by focusing on tumor microenvironment: mesenchymal transition, defined by a remarkable desmoplastic reaction; immune reactive by lymphocytes infiltrating the tumor; solid and proliferative by a solid growth pattern; and papilloglandular by a papillary architecture. Unsupervised hierarchical clustering revealed four clusters correlated with histopathological subtypes in both Kyoto and Niigata HGSOC transcriptome data sets (P < 0.001). Gene set enrichment analysis revealed pathways enriched in our histopathological classification significantly overlapped with the four molecular subtypes: mesenchymal, immunoreactive, proliferative, and differentiated (P < 0.0001, respectively). In 132 HGSOC cases, progression-free survival and overall survival were best in the immune reactive, whereas overall survival was worst in the mesenchymal transition (P < 0.001, respectively), findings reproduced in 89 validation cases (P < 0.05, respectively). The CLOVAR_MES_UP single-sample gene set enrichment analysis scores representing the mesenchymal molecular subtype were higher in paclitaxel responders than nonresponders (P = 0.002) in the GSE15622 data set. Taxane-containing regimens improved survival of cases with high MES_UP scores compared with nontaxane regimens (P < 0.001) in the GSE9891 data set. Our novel histopathological classification of HGSOC correlates with distinct prognostic transcriptome subtypes. The mesenchymal transition subtype might be particularly sensitive to taxane.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26993207     DOI: 10.1016/j.ajpath.2015.12.029

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.

Authors:  Lesley B Conrad; Ken Y Lin; Tulip Nandu; Bryan A Gibson; Jayanthi S Lea; W Lee Kraus
Journal:  Mol Cancer Ther       Date:  2019-10-08       Impact factor: 6.261

2.  Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.

Authors:  Juan Chen; Xiaoyan Shi; Lan Xiao; Zelian Li; Zhimin Li; Lei Sun
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

Review 3.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

4.  Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer.

Authors:  Sotirios Lakis; Vassiliki Kotoula; Georgia-Angeliki Koliou; Ioannis Efstratiou; Sofia Chrisafi; Alexios Papanikolaou; Pantelis Zebekakis; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

Review 5.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

6.  Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.

Authors:  Jennifer Anne Doherty; Lauren Cole Peres; Chen Wang; Gregory P Way; Casey S Greene; Joellen M Schildkraut
Journal:  Curr Epidemiol Rep       Date:  2017-07-10

Review 7.  Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations.

Authors:  Isao Otsuka
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 8.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

9.  Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.

Authors:  Christopher B Morse; Valentin Voillet; Breanna M Bates; Edison Y Chiu; Nicolas M Garcia; Raphael Gottardo; Philip D Greenberg; Kristin G Anderson
Journal:  Gynecol Oncol       Date:  2020-11-20       Impact factor: 5.304

10.  Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.

Authors:  Takuma Ohsuga; Ken Yamaguchi; Aki Kido; Ryusuke Murakami; Kaoru Abiko; Junzo Hamanishi; Eiji Kondoh; Tsukasa Baba; Ikuo Konishi; Noriomi Matsumura
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.